Related Experiment Video
Updated: Jul 30, 2026
Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis:
K J Liu1, G S Chatta, D R Twardzik
1Department of Medicine, University of Washington, Seattle 98195, USA.
Abstract:
The long term goal of this study is to develop autoimmune prostatitis as a therapy for prostate cancer. An immune attack capable of destroying normal prostate epithelial cells should also destroy malignant prostate tissue and provide therapeutic benefit in cancer patients. The current study was initiated to identify antigenic targets for experimental autoimmune prostatitis on the assumption that such proteins might also be suitable targets for immunotherapy of prostate cancer. Male Lewis rats were immunized with syngeneic prostate homogenates, and the immune sera were used to screen prostate proteins for immunoreactivity by Western blot analysis. The dominant protein recognized by the immune sera was purified by ion exchange chromatography and reverse phase HPLC. Microsequence analysis of two polypeptide components of this immunodominant protein demonstrated N-terminal sequences identical with two of the three component chains of rat prostatic steroid-binding protein (PSBP). T cell responses to PSBP were also detected in rats immunized with prostate homogenate. Immunizing male rats with purified PSBP induced vigorous Ab and T cell responses. Significant prostate inflammation was observed in some rats immunized with PSBP. Adoptive transfer of T cells immune to PSBP induced rapid and severe destructive autoimmune prostatitis. These results demonstrate that PSBP is a major target Ag of experimental autoimmune prostatitis in a rat model and may serve as a target Ag for vaccine and T cell therapy against prostate cancer.
Insights
Researchers identified prostatic steroid-binding protein (PSBP) as a key target for autoimmune prostatitis. This finding supports PSBP as a potential target for prostate cancer immunotherapy and vaccines.
Area of Science:
- Immunology
- Oncology
- Urology
Background:
- Prostate cancer immunotherapy aims to leverage immune responses against malignant cells.
- Developing autoimmune prostatitis models can identify therapeutic targets for prostate cancer.
Purpose of the Study:
- To identify antigenic targets for experimental autoimmune prostatitis.
- To evaluate these targets for potential prostate cancer immunotherapy.
Main Methods:
- Rats were immunized with prostate homogenates; immune sera screened for immunoreactivity.
- Dominant protein targets were purified and sequenced.
- T cell responses and autoimmune prostatitis were induced using purified prostatic steroid-binding protein (PSBP).
Main Results:
- Prostatic steroid-binding protein (PSBP) was identified as the dominant antigen.
- PSBP induced robust antibody and T cell responses in rats.
- Adoptive transfer of PSBP-specific T cells caused severe autoimmune prostatitis.
Conclusions:
- Prostatic steroid-binding protein (PSBP) is a major autoantigen in experimental autoimmune prostatitis.
- PSBP serves as a potential target antigen for prostate cancer vaccines and T cell therapies.
